• Criptovalute
  • Mercati Predittivi
  • Notizie
  • Trading Agentico
  • Articoli
  • Leghe

Cerca Criptovalute

Criptovalute di tendenza

CoinRithm

Azienda

Entità legale
Bees-x Limited
Numero società
13308136
Costituita in
England and Wales
Sede legale
Monmouth House, High Street, Watford, England, WD17 1LN

CoinRithm è un servizio di informazione e ricerca gestito da Bees-x Limited. Non è autorizzato dalla Financial Conduct Authority (FCA) a svolgere attività regolamentate e nulla su questo sito costituisce consulenza finanziaria.

Esplora

CriptovaluteMercati PredittiviNotizieArticoliAgent ArenaLeghe

Funzionalità

CruscottoScambio DimostrativoTrading AgenticoPortafoglioLista di ControlloImpostazioni

Azienda

Chi SiamoMetodologiaPer le auleTermini di UsoPolitica sulla RiservatezzaPolitica sui CookieDisconoscimento

Assistenza

Supporto ClientiDomande FrequentiKit per sviluppatoriDocumentazione MCP

Social

X (Twitter)FacebookLinkedInTelegramInstagramTikTokYouTube
© 2026 CoinRithm. Tutti i diritti riservati.
Disponibile su Google PlayScarica su App Store
  • Home
  • MercatiMercati Predittivi
  • Notizie
  • Cruscotto
  1. Mercati Predittivi
  2. China
  3. FDA decision: Ivonescimab by Summit Therapeutics (in 2026)
FDA decision: Ivonescimab by Summit Therapeutics (in 2026)

FDA decision: Ivonescimab by Summit Therapeutics (in 2026)

ChinaOne-OffHealth & Medicine6m
KalshiKalshiVerifica disponibilitàKYC richiesto2% di commissione
Probabilità implicita attuale
Sì
Sì 0%
Qualita del mercato

24 / 100

Bassa qualità
Volume 24h

0 €

Liquidità

0 €

Bassa liquidità
Bid / Ask

54.0% / 62.0%

Spread

14.8%

Spread ampio
Dati di mercato

Aggiornato 11 minuti fa

17 giu 26, 21:001 gen 27, 4:59

Trend

Esito24hProbabilità
Sì
Sì
0%
No
No
100%

Esito scelto

Yes0%

Regole

If the FDA's decision on Ivonescimab by Summit Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.

Kalshi
  • This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
  • Ivonescimab (also called AK112 or SMT112) is a bispecific antibody — think of it as a single engineered drug molecule that carries two different "hooks" instead of one, allowing it to grab and block two disease-promoting proteins at the same time.
  • It was developed by Akeso and is being commercialized outside China by Summit Therapeutics.
  • By simultaneously neutralizing both targets, ivonescimab is designed to slow cancer growth more effectively than drugs that block only one pathway at a time.

Mercati Correlati

Manifold Markets

Will China have more phase 3 drug trials than the United States in year X?

367,9 €
2026: 33%Manifold MarketsMANIFOLD MARKETS
Hantavirus pandemic in 2026?

Hantavirus pandemic in 2026?

38,3K €
Sì: 4%PolymarketPOLYMARKET
New pandemic in 2026?

New pandemic in 2026?

5,9K €
Sì: 11%PolymarketPOLYMARKET
Measles cases in U.S. by June 30?

Measles cases in U.S. by June 30?

2,2K €
2150: 41%PolymarketPOLYMARKET
Manifold Markets

How many movies will gross >$1 billion in 2026?

1,3K €
0-3: 5.7%Manifold MarketsMANIFOLD MARKETS
Manifold Markets

Testosterone unscheduled/rescheduled more permissively in US by end of 2028?

994,7 €
Sì: 22.2%Manifold MarketsMANIFOLD MARKETS

Attivi in questi argomenti

BitcoinBTC$64,780.07-1.50%EthereumETH$1,762.10-1.75%SolanaSOL$72.60-1.38%DogecoinDOGE$0.0865-1.04%XRPXRP$1.19-1.99%BNBBNB$603.90-0.25%

Notizie Correlate

Chinese Man Gets 10+ Years for Stealing 107 BTC Using Memorized KeyBlockchain.NewsPentagon adds Alibaba, Baidu and BYD to China’s military-linked list Crypto NewsNvidia’s CEO declines Senate testimony on China’s AI chip businessCrypto NewsChina warns developers over overseas AI relay servicesCrypto NewsChina court treats Bitcoin as property in 107 BTC theft caseCrypto NewsChinese court treats Bitcoin as property in 107 BTC memory theft caseCointelegraph

Regole

If the FDA's decision on Ivonescimab by Summit Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes.

Kalshi
  • This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
  • Ivonescimab (also called AK112 or SMT112) is a bispecific antibody — think of it as a single engineered drug molecule that carries two different "hooks" instead of one, allowing it to grab and block two disease-promoting proteins at the same time.
  • It was developed by Akeso and is being commercialized outside China by Summit Therapeutics.
  • By simultaneously neutralizing both targets, ivonescimab is designed to slow cancer growth more effectively than drugs that block only one pathway at a time.